574 related articles for article (PubMed ID: 28949122)
41. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
43. Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.
Basu S; Parghane RV
PET Clin; 2017 Jan; 12(1):27-37. PubMed ID: 27863564
[TBL] [Abstract][Full Text] [Related]
44. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
45. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.
Danti G; Flammia F; Matteuzzi B; Cozzi D; Berti V; Grazzini G; Pradella S; Recchia L; Brunese L; Miele V
Radiol Med; 2021 Dec; 126(12):1497-1507. PubMed ID: 34427861
[TBL] [Abstract][Full Text] [Related]
46. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
47. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
48. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Kim MK; Rinke A; Bergestuen DS; Thirlwell C; Khan MS; Salazar R; Oberg K
Neuroendocrinology; 2014; 99(2):63-74. PubMed ID: 24458014
[TBL] [Abstract][Full Text] [Related]
49. PET imaging in endocrine tumours.
Khan S; Lloyd C; Szyszko T; Win Z; Rubello D; Al-Nahhas A
Minerva Endocrinol; 2008 Jun; 33(2):41-52. PubMed ID: 18414356
[TBL] [Abstract][Full Text] [Related]
50. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
51. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
[TBL] [Abstract][Full Text] [Related]
52. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
[TBL] [Abstract][Full Text] [Related]
53. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
Ambrosini V; Nanni C; Fanti S
PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
[TBL] [Abstract][Full Text] [Related]
54. Molecular imaging in the management of thyroid cancer.
Wong KK; Dvorak RA; Marzola MC; Grassetto G; Gross MD; Rubello D
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):541-59. PubMed ID: 22019711
[TBL] [Abstract][Full Text] [Related]
55. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
56. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
Treglia G; Castaldi P; Villani MF; Perotti G; Filice A; Ambrosini V; Cremonini N; Versari A; Fanti S; Giordano A; Rufini V
Recent Results Cancer Res; 2013; 194():385-93. PubMed ID: 22918771
[TBL] [Abstract][Full Text] [Related]
57. Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
Imperiale A; Rust E; Boulanger C; Roedlich MN; Ollier JC; Schneegans O
Clin Nucl Med; 2012 Aug; 37(8):e206-8. PubMed ID: 22785529
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic utility of PETCT in thyroid malignancies: an update.
Palaniswamy SS; Subramanyam P
Ann Nucl Med; 2013 Oct; 27(8):681-93. PubMed ID: 23801405
[TBL] [Abstract][Full Text] [Related]
59. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
60. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
